

# Review of: "Fluoxetine plus lithium for treatment of mental health impairment in Long Covid"

Kenji Hashimoto

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

Mental disability is a serious symptom of long COVID. In this article, the author proposed that combination of lithium and fluoxetine could be new therapeutic drugs for long COVID patients. This hypothesis is interesting although further clinical study is needed. I have one comment about this proposal.

Fluoxetine has been used in the treatment of mental illness such as depression. In addition of SSRI action, fluoxetine is a potent agonist at sigma-1 receptor which may play a role in long COVID (i.e., *Mol Psychiatry*. 2022 Apr;27(4):1898-1907 and *Eur Arch Psychiatry Clin Neurosci*. 2021 Mar;271(2):249-258). Please discuss a potential role of sigma-1 receptor in the beneficial actions of fluoxetine.